

Lumryz (sodium oxybate ext rel)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOFP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION		
LAST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:	
NPI NUMBER:	DEA NUMBER:	
PHONE NUMBER:	FAX NUMBER:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.

Lumryz (sodium oxybate ext rel)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
<input type="checkbox"/> Narcolepsy with cataplexy <input type="checkbox"/> Narcolepsy with excessive daytime sleepiness <input type="checkbox"/> Other Diagnosis _____ ICD-10 Code(s): _____		
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
<p>For all diagnoses, answer the following:</p> <p>Is the prescriber a sleep specialist or neurologist? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Has patient had a minimum 3month trial of immediate release sodium oxybate? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit supporting documentation.</i></p> <p>If patient has tried immediate release sodium oxybate, did patient fail to have their narcolepsy with excessive daytime sleepiness or cataplexy resolved? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit supporting documentation.</i></p> <p>Does patient have an absolute contraindication to immediate release sodium oxybate? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit supporting documentation.</i></p> <p>Select if the following applies to the patient:*</p> <ul style="list-style-type: none"><input type="checkbox"/> A polysomnography (PSG) sleep study consistent with narcolepsy<input type="checkbox"/> A Multiple Sleep Latency Test consistent with narcolepsy<input type="checkbox"/> Chart notes or consultation report documenting diagnosis <p><i>*Please provide supporting documentation.</i></p> <p>For narcolepsy with excessive daytime sleepiness, also answer the following:</p> <p>Is the patient concurrently taking a sedative hypnotic? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Has the patient had a previous trial with standard stimulants such as methylphenidate, dextroamphetamine, or amphetamine/dextroamphetamine?* <input type="checkbox"/> Yes <input type="checkbox"/> No <i>*Please submit supporting documentation showing date(s) of trial(s).</i></p> <p>Has the patient had a previous trial with generic modafinil (Provigil) or Nuvigil (armodafinil)?* <input type="checkbox"/> Yes <input type="checkbox"/> No <i>*Please submit supporting documentation.</i></p> <p>If "no" to the above question, is the patient not a candidate for generic modafinil (Provigil) or Nuvigil (armodafinil)?* <input type="checkbox"/> Yes <input type="checkbox"/> No <i>*Please submit supporting documentation.</i></p>		



Lumryz (sodium oxybate ext rel)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

Has the patient tried the generic sodium oxybate product? Yes No

Does patient have an absolute contraindication to the generic sodium oxybate? Yes No

**Please provide supporting chart notes.*

If the patient has tried the authorized generic sodium oxybate and will not be continuing it, has a U.S. FDA MedWatch Voluntary Reporting Form for adverse drug reactions (FDA Form 3500) been filed with the FDA?

Yes No *Please submit a copy of the completed FDA 3500 form.*

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnoses are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP - 4201

P.O. Box 64811

St. Paul, MN 55164-0811